The submission of API information to the FDA by the DMF holder who intends to authorize generic drug applicants to rely on the information to support submissions to the FDA without the holder having to disclose the information to the generic drug applicants.
——源自CA For TypeII API DMFs Under GDUFA
问:
1.上句话结构分析,我推断主句的是The submission of API information to the FDA by the DMF holder having to disclose the information to the generic drug applicants。 但是不明白为什么这里用having这个时态。
2.持有者和制造商之间的关联。制造商是否一定要通过持有者来销售,否则即为违法?